Pharmacological management of treatment-resistant obsessive-compulsive disorder

A Abudy, A Juven-Wetzler, J Zohar - CNS drugs, 2011 - Springer
A Abudy, A Juven-Wetzler, J Zohar
CNS drugs, 2011Springer
Once considered rare and resistant to treatment, obsessive-compulsive disorder (OCD) has
now emerged as a common, yet often unrecognized, psychiatric condition. Treatment with
selective serotonin reuptake inhibitors (SSRIs) is effective in 40–60% of patients with OCD.
Management of the remaining 40–60% of patients with treatment-resistant OCD is
challenging. We review up-to-date evidence focusing on strategies for treatment-resistant
OCD, including increasing the dose of SSRI, switching to another SSRI, augmentation with …
Abstract
Once considered rare and resistant to treatment, obsessive-compulsive disorder (OCD) has now emerged as a common, yet often unrecognized, psychiatric condition. Treatment with selective serotonin reuptake inhibitors (SSRIs) is effective in 40–60% of patients with OCD. Management of the remaining 40–60% of patients with treatment-resistant OCD is challenging.
We review up-to-date evidence focusing on strategies for treatment-resistant OCD, including increasing the dose of SSRI, switching to another SSRI, augmentation with antipsychotics, and the use of serotonin nor-adrenaline (norepinephrine) reuptake inhibitors (SNRIs) and monoamine oxidase inhibitors (MAOIs). Finally, we provide a flow chart, which includes nonpharmacological interventions such as cognitive-behavioural therapy, family interventions and physical interventions such as neurosurgery and deep brain stimulation, alongside the pharmacological strategies.
Springer